{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T13:36:29Z","timestamp":1777901789238,"version":"3.51.4"},"reference-count":29,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100000897","name":"Cystic Fibrosis Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000897","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100020729","name":"Choquette Family Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100020729","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","cysticfibrosisjournal.com","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Cystic Fibrosis"],"published-print":{"date-parts":[[2025,1]]},"DOI":"10.1016\/j.jcf.2024.07.004","type":"journal-article","created":{"date-parts":[[2024,7,10]],"date-time":"2024-07-10T03:39:30Z","timestamp":1720582770000},"page":"83-90","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Efficacy and safety of LAU-7b in a Phase 2 trial in adults with cystic fibrosis"],"prefix":"10.1016","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0557-7277","authenticated-orcid":false,"given":"Michael W.","family":"Konstan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Deepika","family":"Polineni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4495-4693","authenticated-orcid":false,"given":"James F.","family":"Chmiel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0224-8715","authenticated-orcid":false,"given":"Lara","family":"Bilodeau","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3361-4941","authenticated-orcid":false,"given":"Peter G.","family":"Middleton","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8327-4837","authenticated-orcid":false,"given":"Elias","family":"Matouk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-7373-823X","authenticated-orcid":false,"given":"Jean-Marie","family":"Houle","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Radu","family":"Pislariu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patrick","family":"Colin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-0420-1098","authenticated-orcid":false,"given":"Irenej","family":"Kianicka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-8627-5180","authenticated-orcid":false,"given":"Diane","family":"Potvin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Danuta","family":"Radzioch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5271-4924","authenticated-orcid":false,"given":"Tom","family":"Kotsimbos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8190-9210","authenticated-orcid":false,"given":"Jonathan B.","family":"Zuckerman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4124-316X","authenticated-orcid":false,"given":"Samya Z.","family":"Nasr","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Theodore G.","family":"Liou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2478-4412","authenticated-orcid":false,"given":"Larry C.","family":"Lands","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.jcf.2024.07.004_bib0001","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1016\/j.jcf.2022.01.009","article-title":"Worldwide rates of diagnosis and effective treatment for cystic fibrosis","volume":"21","author":"Guo","year":"2022","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.jcf.2024.07.004_bib0002","doi-asserted-by":"crossref","first-page":"4485","DOI":"10.1007\/s00018-020-03540-9","article-title":"Dysregulated signalling pathways in innate immune cells with cystic fibrosis mutations","volume":"77","author":"Lara-Reyna","year":"2020","journal-title":"Cell Mol Life Sci"},{"key":"10.1016\/j.jcf.2024.07.004_bib0003","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1164\/rccm.200901-0069OC","article-title":"Lung disease at diagnosis in infants with cystic fibrosis detected by newborn screening","volume":"180","author":"Sly","year":"2009","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jcf.2024.07.004_bib0004","first-page":"1075","article-title":"Early pulmonary inflammation in infants with cystic fibrosis","volume":"151","author":"Khan","year":"1995","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jcf.2024.07.004_bib0005","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1002\/ppul.1950200203","article-title":"The relationship between infection and inflammation in the early stages of lung disease from cystic fibrosis","volume":"20","author":"Balough","year":"1995","journal-title":"Pediatr Pulmonol"},{"key":"10.1016\/j.jcf.2024.07.004_bib0006","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1002\/(SICI)1099-0496(199708)24:2<137::AID-PPUL13>3.0.CO;2-3","article-title":"Current understanding of the inflammatory process in cystic fibrosis - onset and etiology","volume":"24","author":"Konstan","year":"1997","journal-title":"Pediatr Pulmonol"},{"key":"10.1016\/j.jcf.2024.07.004_bib0007","doi-asserted-by":"crossref","first-page":"1963","DOI":"10.1056\/NEJMoa1301725","article-title":"Risk factors for bronchiectasis in children with cystic fibrosis","volume":"368","author":"Sly","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jcf.2024.07.004_bib0008","doi-asserted-by":"crossref","first-page":"4052","DOI":"10.3390\/ijms24044052","article-title":"Respiratory infection and inflammation in cystic fibrosis: a dynamic interplay among the host, microbes, and environment for the ages","volume":"24","author":"Yu","year":"2023","journal-title":"Int. J. Mol. Sci."},{"issue":"18","key":"10.1016\/j.jcf.2024.07.004_bib0009","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1056\/NEJMoa1105185","article-title":"Elborn JS for the VX-08-770-102 Study Group. A CFTR potentiator in patients with cystic fibrosis and the G551D Mutation","volume":"365","author":"Ramsey","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jcf.2024.07.004_bib0010","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1056\/NEJMoa1908639","article-title":"Elexacaftor-tezacaftor-ivacaftor for cystic fibrosis with a single Phe508del allele","volume":"381","author":"Middleton","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jcf.2024.07.004_bib0011","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1513\/AnnalsATS.201907-493OC","article-title":"Changes in airway microbiome and inflammation with ivacaftor treatment in patients with cystic fibrosis and the G551D mutation","volume":"17","author":"Harris","year":"2020","journal-title":"Ann Am Thorac Soc"},{"key":"10.1016\/j.jcf.2024.07.004_bib0012","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.02153-2022","article-title":"Longitudinal effects of elexacaftor\/tezacaftor\/ivacaftor on sputum viscoelastic properties, airway infection and inflammation in patients with cystic fibrosis","volume":"62","author":"Schaupp","year":"2023","journal-title":"Euro Respirat J"},{"key":"10.1016\/j.jcf.2024.07.004_bib0013","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1164\/rccm.202210-1938LE","article-title":"& Sermet-gaudelus, i. moving the dial on airway inflammation in response to trikafta in adolescents with cystic fibrosis","volume":"207","author":"Lepissier","year":"2023","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jcf.2024.07.004_bib0014","doi-asserted-by":"crossref","DOI":"10.1172\/JCI167957","article-title":"Pharmacologic improvement of CFTR function rapidly decreases sputum pathogen density, but lung infections generally persist","volume":"133","author":"Nichols","year":"2023","journal-title":"J Clin Invest"},{"issue":"24","key":"10.1016\/j.jcf.2024.07.004_bib0015","doi-asserted-by":"crossref","first-page":"13995","DOI":"10.1073\/pnas.96.24.13995","article-title":"A membrane lipid imbalance plays a role in the phenotypic expression of cystic fibrosis in cftr(-\/-) mice","volume":"96","author":"Freedman","year":"1999","journal-title":"Proc Natl Acad Sci U S A."},{"issue":"2","key":"10.1016\/j.jcf.2024.07.004_bib0016","article-title":"Fenretinide favorably affects mucins (MUC5AC\/MUC5B) and fatty acid imbalance in a manner mimicking CFTR-induced correction","volume":"1865","author":"Gari\u0107","year":"2020","journal-title":"Biochim Biophys Acta Mol Cell Biol Lipids"},{"issue":"1","key":"10.1016\/j.jcf.2024.07.004_bib0017","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1165\/rcmb.2008-0279OC","article-title":"Cystic fibrosis fatty acid imbalance is linked to ceramide deficiency and corrected by fenretinide","volume":"41","author":"Guilbault","year":"2009","journal-title":"Am J Respir Cell Mol Biol. Am J Respir Cell Mol Biol."},{"issue":"10","key":"10.1016\/j.jcf.2024.07.004_bib0018","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1007\/s00109-017-1564-y","article-title":"Fenretinide differentially modulates the levels of long- and very long-chain ceramides by downregulating Cers5 enzyme: evidence from bench to bedside","volume":"95","author":"Gari\u0107","year":"2017","journal-title":"J Mol Med (Berl)"},{"issue":"3","key":"10.1016\/j.jcf.2024.07.004_bib0019","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1007\/s00408-020-00353-2","article-title":"Age-dependent progression in lung pathophysiology can be prevented by restoring fatty acid and ceramide imbalance in cystic fibrosis","volume":"198","author":"Youssef","year":"2020","journal-title":"Lung"},{"key":"10.1016\/j.jcf.2024.07.004_bib0020","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2022.876842","article-title":"Treatment with LAU-7b complements CFTR modulator therapy by improving lung physiology and normalizing lipid imbalance associated with CF lung disease","volume":"13","author":"Centorame","year":"2022","journal-title":"Front. Pharmacol."},{"issue":"10","key":"10.1016\/j.jcf.2024.07.004_bib0021","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1056\/NEJM199409083311003","article-title":"Effect of aerosolized recombinant human DNase on exacerbations of respiratory symptoms and on pulmonary function in patients with cystic fibrosis. The Pulmozyme Study Group","volume":"331","author":"Fuchs","year":"1994","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.jcf.2024.07.004_bib0022","doi-asserted-by":"crossref","first-page":"1610","DOI":"10.1378\/chest.08-1190","article-title":"Determination of the minimal clinically important difference scores for the cystic fibrosis questionnaire-revised respiratory symptom scale in two populations of patients with cystic fibrosis and chronic pseudomonas aeruginosa airway infection","volume":"135","author":"Quittner","year":"2009","journal-title":"Chest"},{"key":"10.1016\/j.jcf.2024.07.004_bib0023","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1016\/j.jcf.2018.12.004","article-title":"Measuring recovery in health-related quality of life during and after pulmonary exacerbations in patients with cystic fibrosis","volume":"18","author":"Flume","year":"2019","journal-title":"J. Cyst. Fibros."},{"issue":"3","key":"10.1016\/j.jcf.2024.07.004_bib0024","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1183\/09031936.99.13355299","article-title":"Construct and longitudinal validity of a modified Huang clinical scoring system in adult cystic fibrosis patients","volume":"13","author":"Matouk","year":"1999","journal-title":"Eur Respir J"},{"issue":"10","key":"10.1016\/j.jcf.2024.07.004_bib0025","doi-asserted-by":"crossref","first-page":"2036","DOI":"10.1200\/JCO.1993.11.10.2036","article-title":"Five-year administration of fenretinide: pharmacokinetics and effects on plasma retinol concentrations","volume":"11","author":"Formelli","year":"1993","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jcf.2024.07.004_bib0026","doi-asserted-by":"crossref","unstructured":"Camerini T, Mariani L, De Palo G, Marubini E, Di Mauro MG, Decensi A, Costa A, Veronesi U. Safety of the synthetic retinoid fenretinide: long-term results from a controlled clinical trial for the prevention of contralateral breast cancer journal of clinical oncology, Vol 19, No 6 (March 15), 2001:1664-1670.","DOI":"10.1200\/JCO.2001.19.6.1664"},{"issue":"3","key":"10.1016\/j.jcf.2024.07.004_bib0027","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1016\/j.jcf.2022.12.009","article-title":"Effect of elexacaftor\/tezacaftor\/ivacaftor on annual rate of lung function decline in people with cystic fibrosis","volume":"22","author":"Lee","year":"2023","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.jcf.2024.07.004_bib0028","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.02029-2022","article-title":"Long-term safety and efficacy of elexacaftor\/tezacaftor\/ivacaftor in people with cystic fibrosis and at least one F508del allele: 144-week interim results from a 192-week open-label extension study","volume":"62","author":"Daines","year":"2023","journal-title":"Eur Respir J"},{"issue":"10","key":"10.1016\/j.jcf.2024.07.004_bib0029","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a009779","article-title":"Antibiotic and anti-inflammatory therapies for cystic fibrosis","volume":"3","author":"Chmiel","year":"2013","journal-title":"Cold Spring Harb Perspect Med"}],"container-title":["Journal of Cystic Fibrosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1569199324007896?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1569199324007896?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,1,30]],"date-time":"2025-01-30T22:11:07Z","timestamp":1738275067000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1569199324007896"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1]]},"references-count":29,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,1]]}},"alternative-id":["S1569199324007896"],"URL":"https:\/\/doi.org\/10.1016\/j.jcf.2024.07.004","relation":{},"ISSN":["1569-1993"],"issn-type":[{"value":"1569-1993","type":"print"}],"subject":[],"published":{"date-parts":[[2025,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy and safety of LAU-7b in a Phase 2 trial in adults with cystic fibrosis","name":"articletitle","label":"Article Title"},{"value":"Journal of Cystic Fibrosis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jcf.2024.07.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Published by Elsevier B.V. on behalf of European Cystic Fibrosis Society.","name":"copyright","label":"Copyright"}]}}